Damora Therapeutics, Inc.
DMRA evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $1.67B
- Lead Asset:
- dmr-002 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for DMRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DMRA
Damora Therapeutics, Inc. (DMRA) is a biotechnology company focused on developing antibody-based therapies for mutant-CALR-driven myeloproliferative neoplasms (MPNs), with a lead asset DMR-001 and a cash position of $540.5M as of 2026-06-30 [sec].
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.67B
Cash Runway
—
Lead Asset
dmr-002 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates for Damora Therapeutics, Inc..
Similar companies
Damora Therapeutics, Inc. (DMRA) is a biotechnology company focused on developing antibody-based therapies for mutant-CALR-driven myeloproliferative neoplasms (MPNs), with a lead asset DMR-001 and a cash position of $540.5M as of 2026-06-30 [sec].
- Cash & equivalents of $540.5M as of 2026-06-30 [sec].
- Net loss of $31.2M for the period ending 2026-06-30 [sec].
- Lead asset DMR-001 is an Fc null antibody targeting mutCALR-driven MPNs; IND or CTA submission expected mid-2026 [news · 2026-03-19].
- Company has deprioritized legacy asset GB3226 (ENL-YEATS/FLT3 inhibitor for AML) to focus on mutCALR portfolio [sec_mda · as of 2026-03-19].
- Shareholders' equity of $516.1M as of 2026-06-30 [sec].
What works
- Strong cash position of $540.5M as of 2026-06-30, expected to fund operations into Phase 3 development of DMR-001 [sec] [news · 2026-03-19].
- Differentiated portfolio of multiple antibody mechanisms (Fc null, afucosylated, bi-specific T-cell engager) designed to address the full spectrum of mutCALR MPN patients [sec_mda · as of 2026-08-10].
- Clear near-term regulatory milestones: DMR-001 IND/CTA mid-2026, DMR-002 IND/CTA second half 2026, DMR-003 IND/CTA 2027 [sec_mda · as of 2026-03-19] [news · 2026-03-19].
What to weigh
- Company has no approved products and expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2025-11-06].
- Legacy assets (GB3226, GB1211) have been deprioritized, and the company may need to seek partnerships or additional capital to advance them [sec_mda · as of 2026-03-19] [sec_mda · as of 2025-11-06].
- If adequate funding is not secured, the company may be forced to delay, scale back, or eliminate development programs [sec_mda · as of 2025-11-06].
From the filings
Quoted directly from source documents.
DMR-001 IND or CTA submission expected mid-2026
“DMR-001 on track for IND or CTA submission in mid-2026”
News · March 19, 2026
Company deprioritized GB3226 to focus on mutCALR portfolio
“we have determined to focus on our mutCALR portfolio to address the full mutCALR MPN disease spectrum and have deprioritized continued development of GB3226”
SEC MD&A · March 19, 2026
Portfolio includes DMR-001 (Fc null), DMR-002 (afucosylated), DMR-003 (bi-specific T-cell engager)
“This includes our lead asset DMR-001, an Fc null antibody, as well as DMR-002, an afucosylated antibody, and DMR-003, a bi-specific T-cell engager.”
SEC MD&A · August 10, 2026
Risks & what to watch (3)›
Key risks
- No approved products — Company has no marketed products and expects net losses for the foreseeable future [sec_mda · as of 2025-11-06].
- Funding dependency — If additional capital is not secured, the company may need to delay or eliminate programs [sec_mda · as of 2025-11-06].
- Deprioritized legacy assets — GB3226 and GB1211 are deprioritized; partnerships or additional funding needed for their advancement [sec_mda · as of 2026-03-19].
What to watch
- DMR-001 IND or CTA submission expected mid-2026 [news · 2026-03-19].
- DMR-002 IND or CTA submission expected second half of 2026 [sec_mda · as of 2026-03-19].
- First clinical proof-of-concept datasets for DMR-001 expected beginning mid-2027 [news · 2026-03-19].
- Potential corporate partnerships or collaborations for legacy assets (GB3226, GB1211) [sec_mda · as of 2026-03-19].
Sources: News · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Damora Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Damora Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.05 · 0% dilution
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
65
Total value held
$1.45B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,045,481 | $234.3M |
| fairmount funds management llc | 8,713,000 | $225.7M |
| avoro capital advisors llc | 3,783,000 | $98.0M |
| venrock adviser, llc | 3,603,595 | $93.3M |
| fcpm iii services b.v. | 2,441,000 | $63.2M |
| ra capital management, l.p. | 2,399,310 | $62.1M |
| janus henderson group plc | 2,362,696 | $61.4M |
| viking global investors lp | 2,311,082 | $59.9M |
| bellevue group ag | 2,298,000 | $59.5M |
| remedium capital partners, llc | 2,045,473 | $53.0M |
Showing top 10 of 65 institutional holders of Damora Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 1.4%
- Days to cover
- 3.0
- Shares short
- 827,221
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DMRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Damora Therapeutics, Inc.?
Damora Therapeutics, Inc. (DMRA) is a biotechnology company focused on developing antibody-based therapies for mutant-CALR-driven myeloproliferative neoplasms (MPNs), with a lead asset DMR-001 and a cash position of $540.5M as of 2026-06-30 [sec].
What is Damora Therapeutics, Inc.'s lead drug candidate?
Damora Therapeutics, Inc.'s most advanced tracked candidate is dmr-002 (Phase 1) for myeloproliferative neoplasms (MPNs) driven by mutCALR.
Who is the CEO of Damora Therapeutics, Inc.?
Ms. Jennifer A. Jarrett M.B.A. is the chief executive officer of Damora Therapeutics, Inc. (DMRA).
Where is Damora Therapeutics, Inc. headquartered?
Damora Therapeutics, Inc. (DMRA) is headquartered in Waltham, MA, United States.
What therapeutic areas does Damora Therapeutics, Inc. focus on?
Damora Therapeutics, Inc. develops therapies across Oncology, Hematology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.